Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

PHASE3RecruitingINTERVENTIONAL
Enrollment

348

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Long COVID
Interventions
DRUG

Pirfenidone

"Initial dose titration:~First week (days 1-7): 1 capsule (267 mg), 3 times daily (801 mg/day)~Second week (days 8-14): 2 capsules (534 mg), 3 times daily (1602 mg/day)~Maintenance dose:~Third week and thereafter (days 15-90): 3 capsules (801 mg), 3 times daily (2403 mg/day)"

DRUG

Placebo for pirfenidone

"First week (days 1-7): 1 capsule, 3 times daily~Second week (days 8-14): 2 capsules, 3 times daily~Third week and thereafter (days 15-90): 3 capsules, 3 times daily"

DRUG

Upadacitinib

1 capsule (15 mg), once daily for 90 days

DRUG

Placebo for upadacitinib

1 capsule, once daily for 90 days

Trial Locations (8)

10005

NOT_YET_RECRUITING

Joint Clinical Research Centre (JCRC), Kampala

10100

NOT_YET_RECRUITING

University Teaching Hospital, Lusaka

92101

RECRUITING

Laura Rodriguez Research Institute, San Diego

21040-900

NOT_YET_RECRUITING

Ini-Fiocruz, Rio de Janeiro

H2W 1R7

RECRUITING

Institut de Recherches Cliniques de Montréal (IRCM), Montreal

J1H 5N4

NOT_YET_RECRUITING

Centre de Recherche du CHUS (CRCHUS), Sherbrooke

00149

NOT_YET_RECRUITING

INMI Lazzaro Spallanzani IRCCS, Roma

00185

NOT_YET_RECRUITING

Sapienza Università di Roma, Roma

All Listed Sponsors
lead

Douglas D. Fraser

OTHER

NCT06928272 - Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | Biotech Hunter | Biotech Hunter